WHO chief scientist disappointed by CureVac trial
- 3 years ago
The World Health Organization's chief scientist said on Friday that results from the CureVac COVID-19 vaccine's initial trial were disappointing.
German biotech firm CureVac' (5CV.DE) vaccine proved only 47% effective in an initial trial read-out.
"It was disappointing to see the results from CureVac," the WHO's Soumya Swaminathan told a news conference.
Comments